News: Unicyte submits Clinical Trial Application for potentially life-saving therapy
Unicyte submits Clinical Trial Application for potentially life-saving therapy for pediatric patients with urea cycle disorders, setting the stage for patient enrollment in H2 2022 Unicyte AG, a clinical-stage development company innovating the field of regenerative medicine, today announced the submission of a Clinical Trial Application (CTA) in Europe for a Phase 2 trial (reLiver-2) designed to assess the safety and efficacy of its proprietary human liver stem cell (HLSC) therapy, HLSC-001, in pediatric patients with early-onset urea cycle disorders (UCD). HLSC-001 is being evaluated in these patients initially as a bridging therapy prior to liver transplantation with the option and ultimate goal to provide a curative therapy. The company expects to initiate patient enrollment in the second half of
by Spada M, Porta F, Righi D, Gazzera C, Tandoi F, Ferrero I, Fagioli F, Sanchez MBH, Calvo PL, Biamino E, Bruno S, Gunetti M, Contursi C, Lauritano C, Conio A, Amoroso A, Salizzoni M, Silengo L, Camussi G, Romagnoli R.